Login to Your Account

CSL, Talecris Drop Merger Plans Under FTC Pressure

By Donna Young

Tuesday, June 9, 2009
Australian biotech CSL Ltd. and Talecris Biotherapeutics Inc. decided to abandon their $3.1 billion merger agreement rather than fight the Federal Trade Commission, which filed a suit to block the deal. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription